Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents

Sponsor
Vanderbilt-Ingram Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04310345
Collaborator
National Institutes of Health (NIH) (NIH)
60
1
1
35
1.7

Study Details

Study Description

Brief Summary

This study will evaluate the effects of human-animal interaction on reducing anxiety, depression, worry, and pain and enhancing quality of life in children ages 8-17 years old with a life threatening cancer and their parent caregivers.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Animal-Assisted Interactions
N/A

Detailed Description

Objectives:
  • To examine the feasibility of human-animal interaction (HAI) sessions for children with a life threatening cancer and a primary caregiver, specifically to:

  • To identify and document necessary modifications for a safe and feasible intervention

  • To obtain recruitment estimates and determine potential recruitment barriers

  • To evaluate elements of implementation fidelity (design, training, delivery/receipt of treatment, enactment)

  • To verify safety

  • To determine the preliminary efficacy of human-animal interaction sessions:

  • On children with a life threatening cancer for the outcomes of qualify of life, anxiety, depression, worry, and pain

  • On caregivers of children with a life threatening cancer for the outcomes of stress and anxiety

Exploratory Objective:
  • To explore mechanisms (reduced salivary cortisol and urinary norepinephrine levels) associated with 8 weeks of human-animal interaction.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Exploring the Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
Actual Study Start Date :
Mar 31, 2021
Anticipated Primary Completion Date :
Mar 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Animal-Assisted Interaction

Children and their caregivers will spend approximately 10-15 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.

Behavioral: Animal-Assisted Interactions
Child and caregivers will spend approximately 10-5 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.

Outcome Measures

Primary Outcome Measures

  1. Pediatric Quality of Life [Up to 2 months]

    The Peds Quality of Life measure will be administered to children and their parents (proxy) at baseline and once a month

  2. Anxiety [Up to 2 months]

    The state-trait anxiety inventory will be administered to children and their parents at baseline and once a month

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Child:
  • Children age 8-17 years old that have been diagnosed with advanced cancer as defined by any stage of relapsed, recurrent or refractory cancer

  • Able to understand English or Spanish to complete consents and surveys

Parent or Guardian:
  • Parent or guardian as determined by person who brings child to >50% of their clinic visits

  • Able to understand English or Spanish to complete consents and surveys

Exclusion Criteria for both Children and Parent/Guardian:
  • Self-reported fear of or allergies to canines

  • Cognitive impairment as identified by healthcare team or inability to complete consenting process

Contacts and Locations

Locations

Site City State Country Postal Code
1 Monroe Carell Jr Children's Hospital at Vanderbilt Nashville Tennessee United States 37232

Sponsors and Collaborators

  • Vanderbilt-Ingram Cancer Center
  • National Institutes of Health (NIH)

Investigators

  • Principal Investigator: Maryjo Gilmer, PhD, Vanderbilt Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maryjo Gilmer, Principal Investigator, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT04310345
Other Study ID Numbers:
  • VICC PED 2003
First Posted:
Mar 17, 2020
Last Update Posted:
May 11, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of May 11, 2022